Targeting myeloid Klf4 may provide therapeutic benefit to PCa patients via induction of a pro-inflammatory myeloid program and increased density of activated CD8 T cells and CD8:Treg ratio, potentially through effects on macrophage-mediated ECM remodeling. This evidence concerns the gene CD8A and posterior cortical atrophy.